DOCSLIB.ORG

Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W. M. Lenders, M.D., Ph.D., Judith Harvey-White, B.S., Monique Ernst, M.D., Ph.D., Alan Zametkin, M.O., Dennis L. Murphy, M.O., and Irwin J. Kopin, M.D. Tiiis study examined wlzetlzcr tile neuronal and 1-dcprcnyl tlzan with dcbrisoquin (255'¼, compared to a cxtmneuronal sites of action of two 1110110a111i11e oxidase 27% increase). Tlze comparable decreases in plasma (MAO) inlzibitors, 1-deprenyl and debrisoq11i11, could be concentrations of DHPG indicate a similar inhibition of disti11g11islzcd by their effects 011 plasma concentrations of intmncuronal MAO by both drugs. Much larger increases cateclw/a111ine metabolites. Plas111a co11centratio11s of tlzc in 110m1ct11nephrine after 1-deprenyl than after debrisoquin i11tra11euro11al dea111inatcd metabolite of" 11orepi11eplzrine, arc consistent with a site of action of the latter drug directed diiiydroxypiienylglycol WHPG), were decreased by 77'½, at the neuronal rather than the extraneuronal compartment. after debrisoquin and by 64'½, after l-dcpm1yl ad111i11istmtio11. Thus, differential changes in deaminated and O-methylated Plasma conccntmtions of the extmneuronal O-111etlzyl11tcd 11111i11c metabolites allm:us identification of neuronal and 111etabolitc of 11orcpineplzri11e, normctaneplzrine, were extra neuronal sites of action of MAO inhibitors. incrrnsed s11bst11ntiall11 more during treatment zpitfz [Neuropsychopharmacology 15:296-301, 1996] KEY IVORDS: Monoa111inc oxidase; Monomnine oxidase a family with an X-linked point mutation of the MAO-A inhibitors; Catec/10/11mi11es; Met11bolis111; Norcpincplzrine; gene where afflicted males exhibit impaired impulse Non11et1111cpl1ri11c control provides the most compelling evidence for a The monoamine oxidases (MAO) A and B catalyze the role of MAO in the expression of behavior (Brunner et deamination of biogenic amines and represent targets al. 1993). for therapeutic intervention in se\·eral neuropsychiatric Recognizing that MAO is differentially distributed conditions (Murphy et al. 1980; Berry et al. 1994b ). Ab­ among and within tissues and cell types (Berry et al. normal MAO acti\·ity has been implicated in alcohol­ 1994a; Lai et al. 1994; Thorpe et al. 1987) raises the pos­ ism, depression, and other psychiatric disorders (Ger­ sibility that involvement of the enzyme in different neu­ shon et al. 1979; Devor et al. 1993), but the discovery of ropsychiatric conditions might depend on regional ab­ normalities in MAO activity. Targeting therapeutic interventions to specific tissues or cell types would From the Clinical l\ieuroscie>ncl' Branch, National Institute ot therefore provide a means for tailoring treatment to the Neurological Disorders and Stroh' (CE, JH-W, lJK), Child Psychia­ try Branch (VIE, AZ). and I.aborator\' of Clinical Science (DLM) . specific neuropsychiatric condition. ."..fational Institute of Mental He,1lth, National Institutes of Health, This study examined whether differences in MAO BPtlwsda, :vL1r\'land; and DPpartnwnt of 'Vledicin<' (JW\.1L), Di\'ision activity among neuronal and extraneuronal compart­ of General Internal Medicine, St. Radboud Uni\·ersit\' Hospital, Nijrnegen, The Netherlands. ments can be distinguished using plasma concentra­ Address corrl'spondencl' to: Craenll' Eist>nhofer, Ph.D., Building tions of catecholamine metabolites. Dihydroxyphenyl­ 10, Room 'iN21-I, National Institutl's ot Health, 10 Center Driw. glycol (DHPG)r produced largely by deamination of \.1SC 1-12-1, Betht'SL"Li, .\1D 20892-1-12-1. RecL•in•d August 17. l 99~; re\ isl'd October 17, 1LJ9'i; accepted norepinephrine within sympathetic neurons (Goldstein October 18, i 'J95. et al. 1988) proYided an index of intraneuronal MAO ac- N!:LRCll 1'.--,\l'ffl)['II \R\\.\(_l))t_)C) ]LJlJ()-\tl[. 1;, \.t).) :D 1LJ96 American Colll'ge of 1'europs\·chopharrnarnlog\' Published bv Else\·ier Science Inc. 0893-133X/96/$15 00 655 An'nut,-of the Americas, New York,;\, Y llJ()]() SSDI 0893-133X(95)00233-2 NEUROPSYCHOPHARMACOLOGY 19%-VOL. 15, 'JO.~ Intra- and Extraneuronal Monoamine Oxidase 297 tivity. Normetanephrine and metanephrine, O-methy­ Blood samples (10 ml) were collected by venipuncture lated metabolites of norepinephrine and epinephrine from a forearm vein with subjects in the semi-supine and substrates for extraneuronal MAO, were indices of position. The data presented here represent results for extraneuronal MAO activity. Other measurements of samples drawn before and during the last week during the catecholamine precursor, dihydroxyphenylalanine which subjects received 1-deprenyl. (DOPA), and of the dopamine metabolite, dihydroxy­ phenylacetic acid (DOPAC), provided indices of ty­ Processing of Blood Samples rosine hydroxylase activity and dopamine deamination. Intraneuronal MAO was inhibited with debrisoquin, a Blood samples were transferred into tubes containing drug that is concentrated in sympathetic nerves by neu­ heparin or EDTA and centrifuged to separate the ronal uptake (Giachetti and Shore 1967; Medina et al. plasma. The plasma was removed and stored at -80°C 1969; Pettinger et al. 1969). The effects of debrisoquin until assayed for concentrations of catechols and metab­ were compared with those of 1-deprenyl, administered olites. Plasma concentrations of norepinephrine, epi­ at a dose sufficient to cause inhibition of both MAO-A nephrine, DHPG, DOPA, and DOPAC were estimated and MAO-B. by liquid chromatography with electrochemical detec­ tion after alumina extraction (Eisenhofer et al. 1986). Plasma concentrations of normetanephrine and meta­ METHODS nephrine were also estimated using liquid chromatog­ Subjects raphy with electrochemical detection following extrac­ tion on solid-phase ion-exchange columns (Lenders et The study population included 26 healthy volunteers al. 1993). Plasma concentrations of sulfate-conjugated (mean ::+:: SD, age 45 ::+:: 24 years) and 14 patients with at­ normetanephrine and metanephrine were estimated tention-deficit hyperacti\·ity disorder (mean ::+:: SD, age similarly after incubation of 200-µl samples of plasma 36 ::+:: 7 years). Subjects included 34 males and 6 females. with sulfatase (Sigma Chemical Co., St Louis, MO) at Women of childbearing potential were excluded. Exper­ 37°C for 30 minutes. imental protocols were approved by the intramural re­ view boards of the two institutes involved in the study Statistical Methods and subjects gave written informed consent to participate. Differences in plasma concentrations of catecholamines, Procedures DOPA, and metabolites before and during treatment with MAO inhibitors were assessed using the Student's Debrisoquin was obtained as a gift from Hoffman-La paired t-test. Differences in changes in concentrations Roche (Nutley, I\J) and formulated for administration during treatment with 1-deprenyl versus debrisoquin as tablets in the National Institutes of Health pharmacy. were assessed by two-way analysis of variance (ANOVA). The drug was administered to 26 normal volunteers at Because of the nature of the within-subjects study de­ graded doses over a 9-day inpatient stay at the Clinical sign, variances in changes in concentrations before and Center, National Institutes of Health. During the first 3 during MAO inhibitor treatment are shown using stan­ days, subjects were administered placebo tablets. On dard errors of the differences. the fourth and fifth days, subjects were administered 10 mg of debrisoquin daily. The dose was increased to 20 mg a day lWer the next 2 days and to 40 mg a day dur­ RESULTS ing the last 2 days. Total daily doses were divided into four equal doses deli\·ered 6 hours apart. Blood samples Plasma concentrations of norepinephrine were de­ (10 ml) were collected by venipuncture from a forearm creased by 20'½, to 26% during treatment with debriso­ vein with subjects in the supine position. The data pre­ quin (p < .001) or 1-deprenyl (p < .05), whereas plasma sented here represent results for samples drawn on the concentrations of epinephrine were unaffected (Table third and the last day on which subjects received de­ 1 ). Plasma concentrations of the catecholamine precur­ brisoquin. sor DOPA were decreased by 47% during treatment L-deprenyl (Selegiline hydrochloride, Eldepryl) was with debrisoquin (p < .001) and by 21 °/4, with 1-deprenyl provided by Somerset Pharmaceuticals Inc (Tampa, FL). (p < .002). Plasma concentrations of the deaminated The drug was administered orally to 14 subjects at a dopamine metabolite DOPAC were decreased similarly dose of 60 mg per day for 6 weeks, a dose previously es­ by 53'\, to 55'¾, during treatment with debrisoquin (p < tablished to cause inhibition of both MAO-A and MAO-B .001) or 1-deprenyl (p < .001), whereas concentrations of (Sunderland et al. 1985). Subjects received 1-deprenyl on DHPG, the deaminated metabolite of norepinephrine an outpatient basis but returned to the clinical center for and epinephrine, were decreased by 77°/o with debriso­ periodic clinical evaluation, including sampling of blood. quin (p < .001) and by 63'1/c, with 1-deprenyl (p < .001). 298 G. Eisenhofer et al. NEUROPSYCHOPHARMACOLOCY 1996-VOL. 15, NO. 3 Table 1. Plasma Concentrations of Catecholamines, DOPA, u DHPG DOPAC and Catecholamine Metabolites before and during < 0 Treatment with Debrisoquin or L-deprenyl 0 Q.. 0 -20 11 Baseline Treatment SED i::. :i::: Norepinephrine Q -40 OS Debrisoquin 20 1.1() 0.81 0.08* 5 L-deprenvl H '-,L.:J.:.. 2.01 0.22* 'i5. -60 Epinephrine .5 Debrisoquin 10
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Summary of Product Characteristics
    Package leaflet: Information for the patient Fluoxetine 20mg Capsules, hard fluoxetine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. •If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What Fluoxetine is and what it is used for 2. What you need to know before you take Fluoxetine 3. How to take Fluoxetine 4. Possible side effects 5. How to store Fluoxetine 6. Contents of the pack and other information 1. What Fluoxetine is and what it is used for The name of your medicine is Fluoxetine 20mg Capsules, hard. It contains the active substance fluoxetine. Fluoxetine belongs to a group of medicines called selective serotonin reuptake inhibitor (SSRI) antidepressants. Fluoxetine can be given to treat the following conditions: Adults: • Major depressive episodes • The symptoms of a condition called obsessive-compulsive disorder (OCD). • The eating disorder bulimia nervosa. This medicine is used alongside psychotherapy for the reduction of binge-eating and purging. Children and adolescents aged 8 years and above: • Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Fluoxetine should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.
    [Show full text]
  • Catecholamine Levels and Activity of Monoamine Oxidase in Some Hypothalamic Structures and in the Pineal Gland of Sheep After Administration of FSH
    Physiol. Res. 45:131-136, 1996 Catecholamine Levels and Activity of Monoamine Oxidase in Some Hypothalamic Structures and in the Pineal Gland of Sheep after Administration of FSH B. PASTOROVA, J. VARADY Department of Comparative Physiology , University of Veterinary Medicine, Kosice, Slovak Republic Receded March 6, 1995 Accepted November 13, 1995 Summary The influence of hormonal preparations of FSH in a dose of 24 mg (480 IU) on levels of catecholamine (dopamine, norepinephrine and epinephrine) and the activity of their degradation enzyme monoamine oxidase (MAO) in the hypothalamic regions regulating the reproductive system of sheep (area preoptica, eminentia mediana, corpus mamillare) and pineal gland were investigated in the ocstrous period employing radiochemical methods. The administration of FSH resulted in significant (p<0.001) increases of dopamine levels in the area preoptica and corpus mamillare of the hypothalamus of sheep as compared to control groups with synchronized oestrus. Hormonal stimulation with FSH increased the levels of hypothalamic norepinephrine in the areas studied and these differences were significant in the eminentia mediana (p<0.05) and corpus mamillare (p<0.05). Significant (p<0.001) changes in epinephrine levels were found in the corpus mamillare and area preoptica (p<0.05). Our results indicate that the administration of FSH caused the most pronounced decrease of MAO activity in corpus mamillare (p<0.001). The pineal gland reacted to the hormonal preparation by decreased levels of norepinephrine and dopamine (p<0.001) and by an increase in MAO activity (p<0.01). We suggest that FSH administration affects catecholamine levels and the activity of monoamine oxidase in the studied areas of the brain of sheep by means of a feedback mechanism.
    [Show full text]
  • Biogenic Amine Reference Materials
    Biogenic Amine reference materials Epinephrine (adrenaline), Vanillylmandelic acid (VMA) and homovanillic norepinephrine (noradrenaline) and acid (HVA) are end products of catecholamine metabolism. Increased urinary excretion of VMA dopamine are a group of biogenic and HVA is a diagnostic marker for neuroblastoma, amines known as catecholamines. one of the most common solid cancers in early childhood. They are produced mainly by the chromaffin cells in the medulla of the adrenal gland. Under The biogenic amine, serotonin, is a neurotransmitter normal circumstances catecholamines cause in the central nervous system. A number of disorders general physiological changes that prepare the are associated with pathological changes in body for fight-or-flight. However, significantly serotonin concentrations. Serotonin deficiency is raised levels of catecholamines and their primary related to depression, schizophrenia and Parkinson’s metabolites ‘metanephrines’ (metanephrine, disease. Serotonin excess on the other hand is normetanephrine, and 3-methoxytyramine) are attributed to carcinoid tumours. The determination used diagnostically as markers for the presence of of serotonin or its metabolite 5-hydroxyindoleacetic a pheochromocytoma, a neuroendocrine tumor of acid (5-HIAA) is a standard diagnostic test when the adrenal medulla. carcinoid syndrome is suspected. LGC Quality - ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Reference materials Product code Description Pack size Epinephrines and metabolites TRC-E588585 (±)-Epinephrine
    [Show full text]
  • Official Protocol Title: NCT Number: NCT02750761
    Official Protocol Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old NCT number: NCT02750761 Document Date: 23-Jun-2017 Tedizolid Phosphate (MK-1986) 1 Protocol TR701-120/MK-1986-013, Amendment 4 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Cubist Pharmaceuticals, LLC, A wholly-owned indirect subsidiary of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) Weystrasse 20, Lucerne 6 Switzerland Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old IND NUMBER: [106,307 (IV) and 125,076 (Oral Suspension)] EudraCT NUMBER: 2015-004595-29 23-Jun-2017 Confidential 04PPD9 Tedizolid Phosphate (MK-1986) 2 Protocol TR701-120, Amendment 4 SUMMARY OF CHANGES: TR701-120 Amendment 4 PRIMARY REASON(S) FOR THIS AMENDMENT: Section Change Rationale 1.0 Synopsis Updated dose for 6 to <12 years from 5 mg/kg to The dose level for the two age groups was adjusted Methodology; 4mg/kg, dose for 2 to <6 years from 5 mg/kg to 6 based on the results of the first interim analysis of the Investigational mg/kg based on the data from interim safety and safety and pharmacokinetic data.
    [Show full text]
  • Catecholamine-Induced Lipolysis in Obesity
    International Journal of Obesity (1999) 23, Suppl 1, 10±13 ß 1999 Stockton Press All rights reserved 0307±0565/99 $12.00 http://www.stockton-press.co.uk/ijo Catecholamine-induced lipolysis in obesity Peter Arner1* 1Department of Medicine, Karolinska Institute at Huddinge University Hospital, CME, S-141 86 Huddinge, Sweden Catecholamines are the only hormones with pronounced lipolytic action in man. A number of in vivo and in vitro studies suggest that there is lipolytic resistance to catecholamines in subcutaneous adipose tissue, which is the major fat depot in obese subjects. This is due to multiple alterations in catecholamine signal transduction, involving decreased expression and function of b2-adrenoceptors, increased function of a2-adrenoceptors and decreased ability of cyclic monophosphate (AMP) to stimulate hormone sensitive lipase. A sedentary life-style, which usually characterizes obesity, may contribute to the catecholamine resistance. However, hereditary=genetic factors may also be involved. Recently, decreased expression and function of hormone sensitive lipase has been found in subcutaneous adipocytes of non-obese subjects with heredity for obesity. In addition, polymorphisms in the genes for b2-adrenoceptors, b3-adrenoceptors and hormone sensitive lipase, associate with obesity. On the other hand, catecholamine-induced lipolysis in visceral adipose tissue is increased in obesity due to increased function of b3- adrenoceptors (major ®nding), decreased function of a2-adrenoceptors and increased ability of cyclic AMP to stimulate lipolysis. When the ®ndings in different adipose regions are considered together, it appears that there is a re- distribution of lipolysis and thereby fatty acid mobilization in obesity, favouring the visceral fat depot.
    [Show full text]
  • Beta-Phenylethylamine, a Small Molecule with a Large Impact
    Article ID: WMC004459 ISSN 2046-1690 Beta-phenylethylamine, a small molecule with a large impact Peer review status: Yes Corresponding Author: Ms. Meredith Irsfeld, Fargo, North Dakota State University - United States of America Submitting Author: Dr. Birgit Pruess, Associate Professor, North Dakota State University, Fargo ND 58108, 58108 - United States of America Other Authors: Mr. Matthew Spadafore, Fargo, North Dakota State University - United States of America Previous Article Reference: http://www.webmedcentral.com/article_view/4409 Article ID: WMC004459 Article Type: Review articles Submitted on:12-Dec-2013, 07:13:25 PM GMT Published on: 13-Dec-2013, 06:22:50 AM GMT Article URL: http://www.webmedcentral.com/article_view/4459 Subject Categories:BIOCHEMISTRY Keywords:neurotransmitter, antimicrobial, food spoilage How to cite the article:Irsfeld M, Spadafore M, Pruess B. Beta-phenylethylamine, a small molecule with a large impact. WebmedCentral BIOCHEMISTRY 2013;4(12):WMC004459 Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source(s) of Funding: 1R15AI089403 from NIH/NIAID Competing Interests: The authors declare no competing interets. WebmedCentral > Review articles Page 1 of 16 WMC004459 Downloaded from http://www.webmedcentral.com on 13-Dec-2013, 10:11:14 AM Beta-phenylethylamine, a small molecule with a large impact Author(s): Irsfeld M, Spadafore M, Pruess B Abstract functional relatives of biogenic amines, we present information on other trace amines and biogenic amines as appropriate. General information about PEA is summarized in Chapter I, including the During a screen of bacterial nutrients as inhibitors of chemical properties of PEA (1.1), its natural Escherichia coli O157:H7 biofilm, the Prub research occurrence and biological synthesis (1.2), and its team made an intriguing observation: among 95 chemical synthesis (1.3).
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Synephrine-Containing Dietary Supplement Precipitating Apical Ballooning Syndrome in a Young Female
    CASE REPORT Korean J Intern Med 2013;28:356-360 http://dx.doi.org/10.3904/kjim.2013.28.3.356 Synephrine-containing dietary supplement precipitating apical ballooning syndrome in a young female Hyemoon Chung1, Sung Woo Kwon2, Tae Hoon Kim3, Ji Hyun Yoon1, Dae Won Ma1, Yoo Mi Park1, and Bum-Kee Hong1 1Division of Cardiology, Apical ballooning syndrome (ABS) is a unique reversible cardiomyopathy that is Department of Internal Medicine, frequently precipitated by emotional or physical stress. In addition, the few drugs Gangnam Severance Hospital, Yonsei University College of reported to precipitate ABS were either illegal or strictly controlled for medical Medicine, Seoul; 2Division use. This paper reports a case of ABS precipitated by a dietary supplement. Our of Cardiology, Department case accentuates the potential risk of dietary supplements containing synephrine, of Internal Medicine, Yongin Severance Hospital, Yonsei which is uncontrolled and available to the general public. Therefore, the Korea University College of Medicine, Food and Drug Administration should regulate these dietary supplements, and Yongin; 3Department of Radiology, Gangnam Severance warn healthcare workers and the general public of the potential hazards of the in- Hospital, Yonsei University discriminate abuse of dietary supplements. College of Medicine, Seoul, Korea Keywords: Takotsubo cardiomyopathy; Dietary supplements; Synephrine Received: November 20, 2011 Revised : December 15, 2011 Accepted: December 20, 2011 Correspondence to Bum-Kee Hong, M.D. Division of Cardiology, Depart- ment of Internal Medicine, Gang- nam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea Tel: +82-2-2019-3311 Fax: +82-2-3463-3463 E-mail: [email protected] INTRODUCTION severe emotional or physical stress [3,4].
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]